[1]
Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010; 9(3): 203-14.
[2]
Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11(3): 191-200.
[3]
Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol 2013; 31(28): 3600-4.
[4]
Breslin S, O’Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 2013; 18(5-6): 240-9.
[5]
Choi SM, Kim Y, Shim JS, et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013; 57(6): 2458-68.
[6]
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8): 711-5.
[7]
Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov 2011; 10(3): 179-87.
[8]
Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 2012; 11(12): 909-22.
[9]
Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59: 1-12.
[10]
Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y) 2017; 3(4): 651-7.
[11]
Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 2012; 11(12): 909-22.
[12]
Ouzounis CA. The emergence of bioinformatics: historical perspective, quick overview and future trends 2009.
[13]
Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE. Soft lithography in biology and biochemistry. Annu Rev Biomed Eng 2001; 3: 335-73.
[14]
Beebe DJ, Mensing GA, Walker GM. Physics and applications of microfluidics in biology. Annu Rev Biomed Eng 2002; 4: 261-86.
[15]
Shamir ER, Ewald AJ. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 2014; 15(10): 647-64.
[16]
Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol 2011; 21(12): 745-54.
[17]
Lee JS, Romero R, Han YM, et al. Placenta-on-a-chip: A novel platform to study the biology of the human placenta. J Matern Fetal Neonatal Med 2016; 29(7): 1046-54.
[18]
Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 2015; 14(4): 248-60.
[19]
Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science 2010; 328(5986): 1662-8.
[20]
Inamdar NK, Borenstein JT. Microfluidic cell culture models for tissue engineering. Curr Opin Biotechnol 2011; 22(5): 681-9.
[21]
Huh D, Leslie DC, Matthews BD, et al. Thorneloe KS, McAlexander MA, Ingber DE. A human disease model of drug toxicity–induced pulmonary edema in a lung-on-a-chip microdevice. Science translational medicine 2012; 4: 159ra147.
[22]
Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008; 26(1): 120-6.
[23]
Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip 2013; 13(18): 3599-608.
[24]
Egert U, Meyer T. Heart on a chip—extracellular multielectrode recordings from cardiac myocytes in vitro. In: ed.^eds., Practical Methods in Cardiovascular Research. Springer, 2005; pp. 432-453.
[25]
Grosberg A, Alford PW, McCain ML, Parker KK. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip 2011; 11(24): 4165-73.
[26]
Jastrzebska E, Tomecka E, Jesion I. Heart-on-a-chip based on stem cell biology. Biosens Bioelectron 2016; 75: 67-81.
[27]
Marsano A, Conficconi C, Lemme M, et al. Beating heart on a chip: A novel microfluidic platform to generate functional 3D cardiac microtissues. Lab Chip 2016; 16(3): 599-610.
[28]
Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies. Nat Med 2014; 20: 616.
[29]
Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 2014; 20(6): 616-23.
[30]
Zhang X, Wang T, Wang P, Hu N. High-throughput assessment of drug cardiac safety using a high-speed impedance detection technology-based Heart-on-a-chip. Micromachines (Basel) 2016; 7(7): 122.
[31]
Zhang YS, Aleman J, Arneri A, et al. From cardiac tissue engineering to heart-on-a-chip: beating challenges. Biomed Mater 2015; 10(3): 034006.
[32]
Zhang YS, Arneri A, Bersini S, et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials 2016; 110: 45-59.
[33]
Dauth S, Maoz BM, Sheehy SP, et al. Neurons derived from different brain regions are inherently different in vitro: A novel multiregional brain-on-a-chip. J Neurophysiol 2017; 117(3): 1320-41.
[34]
Griep LM, Wolbers F, de Wagenaar B, et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed Microdevices 2013; 15(1): 145-50.
[35]
Kilic O, Pamies D, Lavell E, et al. Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis. Lab Chip 2016; 16(21): 4152-62.
[36]
Pamies D, Hartung T, Hogberg HT. Biological and medical applications of a brain-on-a-chip. Exp Biol Med (Maywood) 2014; 239(9): 1096-107.
[37]
Park J, Lee BK, Jeong GS, Hyun JK, Lee CJ, Lee S-H. Three-dimensional brain-on-a-chip with an interstitial level of flow and its application as an in vitro model of Alzheimer’s disease. Lab Chip 2015; 15(1): 141-50.
[38]
Aschheim K, DeFrancesco L, Elsner M, Hare P, Mak C. Lung on a chip. Science 2010; 328: 1662-8.
[39]
Benam KH, Villenave R, Lucchesi C, et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 2016; 13(2): 151-7.
[40]
Huh DD. A human breathing lung-on-a-chip. Ann Am Thorac Soc 2015; 12(Suppl. 1): S42-4.
[41]
Huh D, Fujioka H, Tung Y-C, et al. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. Proc Natl Acad Sci USA 2007; 104(48): 18886-91.
[42]
Konar D, Devarasetty M, Yildiz DV, Atala A, Murphy SV. Lung-On-A-Chip Technologies for Disease Modeling and Drug Development: Supplementary Issue: Image and Video Acquisition and Processing for Clinical Applications. Biomedical engineering and computational biology 2016; S34252.
[43]
Long C, Finch C, Esch M, Anderson W, Shuler M, Hickman J. Design optimization of liquid-phase flow patterns for microfabricated lung on a chip. Ann Biomed Eng 2012; 40(6): 1255-67.
[44]
Punde TH, Wu W-H, Lien P-C, et al. A biologically inspired lung-on-a-chip device for the study of protein-induced lung inflammation. Integr Biol 2015; 7(2): 162-9.
[45]
Stucki AO, Stucki JD, Hall SR, et al. A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab Chip 2015; 15(5): 1302-10.
[46]
Kim HJ, Huh D, Hamilton G, Ingber DE. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 2012; 12(12): 2165-74.
[47]
Kim HJ, Ingber DE. Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr Biol 2013; 5(9): 1130-40.
[48]
Kim HJ, Lee J, Choi J-H, Bahinski A, Ingber DE. Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device. J Vis Exp 2016; (114).
[49]
Kim HJ, Li H, Collins JJ, Ingber DE. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci USA 2016; 113(1): E7-E15.
[50]
Villenave R, Wales SQ, Hamkins-Indik T, et al. Human gut-on-a-chip supports polarized infection of coxsackie B1 virus in vitro. PLoS One 2017; 12(2): e0169412.
[51]
Bavli D, Prill S, Ezra E, et al. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc Natl Acad Sci USA 2016; 113(16): E2231-40.
[52]
Bhise NS, Manoharan V, Massa S, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication 2016; 8(1): 014101.
[53]
Esch MB, Ueno H, Applegate DR, Shuler ML. Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. Lab Chip 2016; 16(14): 2719-29.
[54]
Gori M, Simonelli MC, Giannitelli SM, Businaro L, Trombetta M, Rainer A. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS One 2016; 11(7): e0159729.
[55]
Ho C-T, Lin R-Z, Chang W-Y, Chang H-Y, Liu C-H. Rapid heterogeneous liver-cell on-chip patterning via the enhanced field-induced dielectrophoresis trap. Lab Chip 2006; 6(6): 724-34.
[56]
Ho C-T, Lin R-Z, Chen R-J, et al. Liver-cell patterning lab chip: mimicking the morphology of liver lobule tissue. Lab Chip 2013; 13(18): 3578-87.
[57]
Knowlton S, Tasoglu S. A bioprinted liver-on-a-chip for drug screening applications. Trends Biotechnol 2016; 34(9): 681-2.
[58]
Lee J, Kim SH, Kim Y-C, Choi I, Sung JH. Fabrication and characterization of microfluidic liver-on-a-chip using microsomal enzymes. Enzyme Microb Technol 2013; 53(3): 159-64.
[59]
Yoon No D, Lee KH, Lee J, Lee SH. 3D liver models on a microplatform: well-defined culture, engineering of liver tissue and liver-on-a-chip. Lab Chip 2015; 15(19): 3822-37.
[60]
Lee S-A, No Y, Kang E, Ju J, Kim DS, Lee SH. Spheroid-based three-dimensional liver-on-a-chip to investigate hepatocyte-hepatic stellate cell interactions and flow effects. Lab Chip 2013; 13(18): 3529-37.
[61]
Ha L, Jang K-J, Suh K-Y. Kidney on a Chip In: ed.^eds., Microfluidics for Medical Applications, 2014; pp. 19-39.
[62]
Jang K-J, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol 2013; 5(9): 1119-29.
[63]
Kim S. LesherPerez SC, Kim BC, et al. Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip. Biofabrication 2016; 8(1): 015021.
[64]
Nieskens TT, Wilmer MJ. Kidney-on-a-chip technology for renal proximal tubule tissue reconstruction. Eur J Pharmacol 2016; 790: 46-56.
[65]
Sochol RD, Gupta NR, Bonventre JV. A role for 3D printing in kidney-on-a-chip platforms. Curr Transplant Rep 2016; 3(1): 82-92.
[66]
Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R. Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol 2016; 34(2): 156-70.
[67]
Torisawa YS, Spina CS, Mammoto T, et al. Bone marrow-on-a-chip replicates hematopoietic niche physiology in vitro. Nat Methods 2014; 11(6): 663-9.
[68]
Yasotharan S, Pinto S, Sled JG, Bolz S-S, Günther A. Artery-on-a-chip platform for automated, multimodal assessment of cerebral blood vessel structure and function. Lab Chip 2015; 15(12): 2660-9.
[69]
Jain A, Graveline A, Waterhouse A, Vernet A, Flaumenhaft R, Ingber DE. A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function. Nat Commun 2016; 7: 10176.
[70]
Maschmeyer I, Lorenz AK, Schimek K, et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 2015; 15(12): 2688-99.
[71]
Zhang YS, Aleman J, Shin SR, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proceedings of the National Academy of Sciences 2017; 201612906.
[72]
Wikswo JP, Block FE III, Cliffel DE, et al. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans Biomed Eng 2013; 60(3): 682-90.
[73]
Esch MB, King TL, Shuler ML. The role of body-on-a-chip devices in drug and toxicity studies. Annu Rev Biomed Eng 2011; 13: 55-72.
[74]
Esch MB, Mahler GJ, Stokol T, Shuler ML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip 2014; 14(16): 3081-92.
[75]
Williamson A, Singh S, Fernekorn U, Schober A. The future of the patient-specific Body-on-a-chip. Lab Chip 2013; 13(18): 3471-80.
[76]
Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006; 7(3): 211-24.
[77]
El-Ali J, Sorger PK, Jensen KF. Cells on chips. Nature 2006; 442(7101): 403-11.
[78]
Whitesides GM. The origins and the future of microfluidics. Nature 2006; 442(7101): 368-73.
[79]
Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32(1): 56-67.
[80]
Mak IW, Evaniew N, Ghert M. Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res 2014; 6(2): 114-8.
[81]
Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110(9): 3507-12.
[82]
Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: A systematic review of guidelines for in vivo animal experiments. PLoS Med 2013; 10(7): e1001489.
[83]
Samatov TR, Senyavina NV, Galatenko VV, et al. Tumour-like druggable gene expression pattern of CaCo2 cells in microfluidic chip. Biochip J 2016; 10: 215-20.
[84]
Polini A, Prodanov L, Bhise NS, Manoharan V, Dokmeci MR, Khademhosseini A. Organs-on-a-chip: A new tool for drug discovery. Expert Opin Drug Discov 2014; 9(4): 335-52.
[85]
Jacot JG, McCulloch AD, Omens JH. Substrate stiffness affects the functional maturation of neonatal rat ventricular myocytes. Biophys J 2008; 95(7): 3479-87.
[86]
Cheng W, Klauke N, Smith G, Cooper JM. Microfluidic cell arrays for metabolic monitoring of stimulated cardiomyocytes. Electrophoresis 2010; 31(8): 1405-13.
[87]
Kim K, Taylor R, Sim J, et al. Calibrated micropost arrays for biomechanical characterisation of cardiomyocytes. Micro & Nano Lett 2011; 6: 317-22.
[88]
Cheng W, Klauke N, Sedgwick H, Smith GL, Cooper JM. Metabolic monitoring of the electrically stimulated single heart cell within a microfluidic platform. Lab Chip 2006; 6(11): 1424-31.
[89]
Agarwal A, Farouz Y, Nesmith AP, Deravi LF, McCain ML, Parker KK. Micropatterning alginate substrates for in vitro cardiovascular muscle on a chip. Adv Funct Mater 2013; 23(30): 3738-46.
[90]
McCain ML, Agarwal A, Nesmith HW, Nesmith AP, Parker KK. Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues. Biomaterials 2014; 35(21): 5462-71.
[91]
Reza B, Ali N, Mustafa M, Alireza A, Ali K. Cardiac responsiveness to beta-adrenergics in rats with lead-induced hypertension. Biol Med (Aligarh) 2009; 1: 75-81.
[92]
Juberg EN, Minneman KP, Abel PW. β 1- and β 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol 1985; 330(3): 193-202.
[93]
Gulick T, Pieper SJ, Murphy MA, Lange LG, Schreiner GF. A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of beta-adrenergic responses. Circulation 1991; 84(1): 313-21.
[94]
Desai VG, Herman EH, Moland CL, et al. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model. Toxicol Appl Pharmacol 2013; 266(1): 109-21.
[95]
Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992; 52(1): 194-201.
[96]
Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43(11): 5427-32.
[97]
McCain ML, Sheehy SP, Grosberg A, Goss JA, Parker KK. Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip. Proc Natl Acad Sci USA 2013; 110(24): 9770-5.
[98]
Bouten CV, Dankers PY, Driessen-Mol A, Pedron S, Brizard AM, Baaijens FP. Substrates for cardiovascular tissue engineering. Adv Drug Deliv Rev 2011; 63(4-5): 221-41.
[99]
Miyagawa S, Roth M, Saito A, Sawa Y, Kostin S. Tissue-engineered cardiac constructs for cardiac repair. Ann Thorac Surg 2011; 91(1): 320-9.
[100]
Annabi N, Tsang K, Mithieux SM, et al. Highly elastic micropatterned hydrogel for engineering functional cardiac tissue. Adv Funct Mater 2013; 23(39): 4950-9.
[101]
Radisic M, Park H, Gerecht S, Cannizzaro C, Langer R, Vunjak-Novakovic G. Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc Lond B Biol Sci 2007; 362(1484): 1357-68.
[102]
Radisic M, Park H, Shing H, et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci USA 2004; 101(52): 18129-34.
[103]
Engelmayr GC Jr, Cheng M, Bettinger CJ, Borenstein JT, Langer R, Freed LE. Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater 2008; 7(12): 1003-10.
[104]
Kujala VJ, Pasqualini FS, Goss JA, Nawroth JC, Parker KK. Laminar ventricular myocardium on a microelectrode array-based chip. J Mater Chem B Mater Biol Med 2016; 4: 3534-43.
[105]
Fleischer S, Shapira A, Feiner R, Dvir T. Modular assembly of thick multifunctional cardiac patches. Proceedings of the National Academy of Sciences 2017; 201615728.
[106]
You J-O, Rafat M, Ye GJ, Auguste DT. Nanoengineering the heart: conductive scaffolds enhance connexin 43 expression. Nano Lett 2011; 11(9): 3643-8.
[107]
Dvir T, Timko BP, Brigham MD, et al. Nanowired three-dimensional cardiac patches. Nat Nanotechnol 2011; 6(11): 720-5.
[108]
Silva GA, Czeisler C, Niece KL, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004; 303(5662): 1352-5.
[109]
Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005; 23(1): 47-55.
[110]
Shin SR, Jung SM, Zalabany M, et al. Carbon-nanotube-embedded hydrogel sheets for engineering cardiac constructs and bioactuators. ACS Nano 2013; 7(3): 2369-80.
[111]
Shin SR, Shin C, Memic A, et al. Aligned carbon nanotube-based flexible gel substrates for engineering bio-hybrid tissue actuators. Adv Funct Mater 2015; 25(28): 4486-95.
[112]
Shin SR, Aghaei-Ghareh-Bolagh B, Gao X, et al. Layer-by-layer assembly of 3D tissue constructs with functionalized graphene. Adv Funct Mater 2014; 24(39): 6136-44.
[113]
Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471(7337): 225-9.
[114]
Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011; 32(8): 952-62.
[115]
Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12(1): 101-13.
[116]
Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy Science translational medicine, 2012; 4: 130ra47-130ra47.
[117]
Navarrete EG, Liang P, Lan F, et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013; 128(11)(Suppl. 1): S3-S13.
[118]
Natarajan A, Stancescu M, Dhir V, et al. Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform. Biomaterials 2011; 32(18): 4267-74.
[119]
Xiao L, Hu Z, Zhang W, Wu C, Yu H, Wang P. Evaluation of doxorubicin toxicity on cardiomyocytes using a dual functional extracellular biochip. Biosens Bioelectron 2010; 26(4): 1493-9.
[120]
Xiao L, Liu Q, Hu Z, Zhang W, Yu H, Wang P. A multi-scale electrode array (MSEA) to study excitation–contraction coupling of cardiomyocytes for high-throughput bioassays. Sens Actuators B Chem 2011; 152: 107-14.
[121]
Lin ZC, Xie C, Osakada Y, Cui Y, Cui B. Iridium oxide nanotube electrodes for sensitive and prolonged intracellular measurement of action potentials. Nat Commun 2014; 5: 3206.
[122]
Fendyur A, Spira ME. Toward on-chip, in-cell recordings from cultured cardiomyocytes by arrays of gold mushroom-shaped microelectrodes. Front Neuroeng 2012; 5: 21.
[123]
Hai A, Shappir J, Spira ME. In-cell recordings by extracellular microelectrodes. Nat Methods 2010; 7(3): 200-2.
[124]
Xie C, Lin Z, Hanson L, Cui Y, Cui B. Intracellular recording of action potentials by nanopillar electroporation. Nat Nanotechnol 2012; 7(3): 185-90.
[125]
Lee K-Y, Kim I, Kim S-E, et al. Vertical nanowire probes for intracellular signaling of living cells. Nanoscale Res Lett 2014; 9(1): 56.
[126]
Abbott J, Ye T, Qin L, et al. CMOS nanoelectrode array for all-electrical intracellular electrophysiological imaging. Nat Nanotechnol 2017; 12(5): 460-6.
[127]
Abbott J, Ye T, Ham D, Park H. Optimizing Nanoelectrode Arrays for Scalable Intracellular Electrophysiology. Acc Chem Res 2018; 51(3): 600-8.
[128]
Santoro F, Dasgupta S, Schnitker J, et al. Interfacing electrogenic cells with 3D nanoelectrodes: position, shape, and size matter. ACS Nano 2014; 8(7): 6713-23.
[129]
Dipalo M, Amin H, Lovato L, et al. Intracellular and Extracellular Recording of Spontaneous Action Potentials in Mammalian Neurons and Cardiac Cells with 3D Plasmonic Nanoelectrodes. Nano Lett 2017; 17(6): 3932-9.
[130]
Molleman A. Patch clamping: An introductory guide to patch clamp electrophysiology 2003.
[131]
Tian B, Cohen-Karni T, Qing Q, Duan X, Xie P, Lieber CM. Three-dimensional, flexible nanoscale field-effect transistors as localized bioprobes. Science 2010; 329(5993): 830-4.
[132]
Wightman RM. Detection technologies. Probing cellular chemistry in biological systems with microelectrodes. Science 2006; 311(5767): 1570-4.
[133]
Ewing AG, Strein TG, Lau YY. Analytical chemistry in microenvironments: single nerve cells. Acc Chem Res 1992; 25: 440-7.
[134]
Ieong M, Doris B, Kedzierski J, Rim K, Yang M. Silicon device scaling to the sub-10-nm regime. Science 2004; 306(5704): 2057-60.
[135]
Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5(3): 161-71.
[136]
Ingebrandt S, Yeung C-K, Krause M, Offenhäusser A. Cardiomyocyte-transistor-hybrids for sensor application. Biosens Bioelectron 2001; 16(7-8): 565-70.
[137]
Ingebrandt S, Yeung CK, Staab W, Zetterer T, Offenhäusser A. Backside contacted field effect transistor array for extracellular signal recording. Biosens Bioelectron 2003; 18(4): 429-35.
[138]
Yeung C-K, Ingebrandt S, Krause M, Offenhäusser A, Knoll W. Validation of the use of field effect transistors for extracellular signal recording in pharmacological bioassays. J Pharmacol Toxicol Methods 2001; 45(3): 207-14.
[139]
Patolsky F, Timko BP, Yu G, et al. Detection, stimulation, and inhibition of neuronal signals with high-density nanowire transistor arrays. Science 2006; 313(5790): 1100-4.
[140]
Cohen-Karni T, Timko BP, Weiss LE, Lieber CM. Flexible electrical recording from cells using nanowire transistor arrays. Proc Natl Acad Sci USA 2009; 106(18): 7309-13.
[141]
Cohen-Karni T, Qing Q, Li Q, Fang Y, Lieber CM. Graphene and nanowire transistors for cellular interfaces and electrical recording. Nano Lett 2010; 10(3): 1098-102.
[142]
Pui TS, Agarwal A, Ye F, Balasubramanian N, Chen P. CMOS-Compatible nanowire sensor arrays for detection of cellular bioelectricity. Small 2009; 5(2): 208-12.
[143]
Cohen-Karni T, Casanova D, Cahoon JF, Qing Q, Bell DC, Lieber CM. Synthetically encoded ultrashort-channel nanowire transistors for fast, pointlike cellular signal detection. Nano Lett 2012; 12(5): 2639-44.
[144]
Qing Q, Jiang Z, Xu L, Gao R, Mai L, Lieber CM. Free-standing kinked nanowire transistor probes for targeted intracellular recording in three dimensions. Nat Nanotechnol 2014; 9(2): 142-7.
[145]
Duan X, Gao R, Xie P, et al. Intracellular recordings of action potentials by an extracellular nanoscale field-effect transistor. Nat Nanotechnol 2011; 7(3): 174-9.
[146]
Sakmann B, Neher E. Patch clamp techniques for studying ionic channels in excitable membranes. Annu Rev Physiol 1984; 46: 455-72.
[147]
Luong JH, Habibi-Rezaei M, Meghrous J, Xiao C, Male KB, Kamen A. Monitoring motility, spreading, and mortality of adherent insect cells using an impedance sensor. Anal Chem 2001; 73(8): 1844-8.
[148]
Opp D, Wafula B, Lim J, Huang E, Lo J-C, Lo C-M. Use of electric cell-substrate impedance sensing to assess in vitro cytotoxicity. Biosens Bioelectron 2009; 24(8): 2625-9.
[149]
Xiao C, Lachance B, Sunahara G, Luong JH. Assessment of cytotoxicity using electric cell-substrate impedance sensing: concentration and time response function approach. Anal Chem 2002; 74(22): 5748-53.
[150]
Kammermann M, Denelavas A, Imbach A, et al. Impedance measurement: A new method to detect ligand-biased receptor signaling. Biochem Biophys Res Commun 2011; 412(3): 419-24.
[151]
Smout MJ, Laha T, Mulvenna J, et al. A granulin-like growth factor secreted by the carcinogenic liver fluke, Opisthorchis viverrini, promotes proliferation of host cells. PLoS Pathog 2009; 5(10): e1000611.
[152]
Wang T, Hu N, Cao J, Wu J, Su K, Wang P. A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating. Biosens Bioelectron 2013; 49: 9-13.
[153]
Hu N, Wang T, Wang Q, et al. High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition. Biosens Bioelectron 2015; 67: 146-53.
[154]
Zhang X, Guo L, Zeng H, et al. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment. J Pharmacol Toxicol Methods 2016; 81: 201-16.
[155]
Hu N, Wang T, Wan H, et al. Synchronized electromechanical integration recording of cardiomyocytes. Biosens Bioelectron 2018; 117: 354-65.
Download PDF Flyer